Abstract
A spectrofluorimetric method for the determination of eptifibatide is presented based on its native fluorescence. The type of solvent and the wavelength of maximum excitation and emission were carefully selected to optimize the experimental conditions. Under the specified experimental conditions, the linearities obtained between the emission intensity and the corresponding concentrations of eptifibatide were in the range 0.1-2.5μg/ml for the calibration curve constructed for direct determination of eptifibatide in dosage form and 0.05-2.2μg/ml for the calibration curve constructed in spiked human plasma with a good correlation coefficient (r>0.99). The lower limit of quantification for the calibration curve constructed in human plasma was 0.05μg/ml. Recovery results for eptifibatide in spiked plasma samples and in dosage form, represented as mean±% RSD, were 95.17±1.94 and 100.29±1.33 respectively. The suggested procedures were validated according to the International Conference on Harmonization (ICH) guidelines for the direct determination of eptifibatide in its pure form and dosage form and United States Food and Drug Administration (US FDA) Guidance for Industry, Bioanalytical Method Validation for the assay of eptifibatide in human plasma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Luminescence : the journal of biological and chemical luminescence
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
